A Phase II Study of Ixazomib to Prevent Recurrent or Late Acute or Chronic GVHD within the First Year after Stem Cell Transplantation


Full Title

Open Label Phase II Study of Ixazomib for the Prevention of Recurrent or Late Acute and Chronic Graft-versus-Host Disease at 1-year after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Hematologic Malignancies


Graft-versus-host disease (GVHD) is a potential complication that can occur when someone receives stem cells from a donor. It happens when white blood cells called T cells from the donor attack the tissues of the patient. Acute GVHD occurs shortly after the transplant, usually within three months. Chronic GVHD develops more slowly and occurs later than acute GVHD.

Immunosuppressant drugs such as tacrolimus and cyclosporin are typically used to reduce the risk of GVHD, but they are not always effective. In this study, researchers are evaluating the safety and effectiveness of the drug ixazomib in patients who received a stem cell transplant for a blood cancer and are at risk for GVHD 100 or more days after the transplant. Ixazomib reduces the number of donor T cells, other cells, and substances that cause GVHD. It is used to treat multiple myeloma; its use in this study is considered investigational. Ixazomib is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have received a stem cell transplant from a donor 100 to 150 days before entering the study and be at increased risk for GVHD.
  • Patients must have received tacrolimus or cyclosporin plus methotrexate as a prior regimen to prevent GVHD.
  • This study is for patients age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Doris Ponce at 212-639-4838.